G1 Therapeutics (NASDAQ:GTHX) Price Target Cut to $6.00 by Analysts at Needham & Company LLC

G1 Therapeutics (NASDAQ:GTHX) had its price objective trimmed by Needham & Company LLC from $12.00 to $6.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also weighed in on GTHX. Wedbush restated an outperform rating and issued a $3.00 price objective (down from $5.00) on shares of G1 Therapeutics in a report on Monday, June 24th. HC Wainwright lowered their price objective on G1 Therapeutics from $9.00 to $3.00 and set a buy rating for the company in a research report on Tuesday.

G1 Therapeutics Price Performance

Shares of NASDAQ GTHX opened at $2.28 on Tuesday. The stock’s 50-day moving average is $3.59 and its two-hundred day moving average is $3.57. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.94 and a quick ratio of 2.55. G1 Therapeutics has a 1-year low of $1.08 and a 1-year high of $6.14. The company has a market cap of $119.20 million, a price-to-earnings ratio of -3.68 and a beta of 1.71.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. The company had revenue of $14.48 million during the quarter, compared to analysts’ expectations of $15.21 million. During the same quarter in the previous year, the business posted ($0.53) EPS. Analysts forecast that G1 Therapeutics will post -0.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. boosted its holdings in shares of G1 Therapeutics by 20.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 377,858 shares of the company’s stock valued at $1,632,000 after acquiring an additional 64,790 shares during the period. Acadian Asset Management LLC boosted its stake in G1 Therapeutics by 643.2% during the 1st quarter. Acadian Asset Management LLC now owns 433,709 shares of the company’s stock worth $1,873,000 after purchasing an additional 375,354 shares during the period. Vanguard Group Inc. grew its position in G1 Therapeutics by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,081,573 shares of the company’s stock worth $8,992,000 after purchasing an additional 99,900 shares during the last quarter. SG Americas Securities LLC acquired a new position in G1 Therapeutics in the first quarter valued at $58,000. Finally, FinTrust Capital Advisors LLC raised its holdings in shares of G1 Therapeutics by 154,946.2% in the fourth quarter. FinTrust Capital Advisors LLC now owns 100,780 shares of the company’s stock valued at $307,000 after buying an additional 100,715 shares during the last quarter. Hedge funds and other institutional investors own 24.21% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.